8月11日，Alcon Inc盘后上涨5.94%，报78.0美元/股，成交额128.88万美元。
消息面上，公司当日盘后发布第二季度财报，业绩全面超出市场预期。调整后每股收益为0.84美元，超出分析师一致预期的0.75美元约12%，同比增长10.53%；营收27.82亿美元，高于市场预期的27.69亿美元。此前市场预期本季度营收同比增约5.48%，实际表现优于预期。
回顾近几个季度，公司Q1曾出现营收小幅不及预期但EPS超预期的分化格局，本次Q2实现营收与利润双双超预期，叠加7月与RxSight达成可调节老花矫正人工晶体合作，产品线拓展前景明朗，市场反应积极。
Alcon Inc是一家以研发为主导的全球眼部护理医疗公司，产品覆盖药品、手术设备及消费者眼部护理，拥有眼科领域最大规模的研发投入之一。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.